A LONG-TERM FOCUS
ON INNOVATION

We collaborate with leading industry and academic partners and welcome opportunities to engage in discussions related to:

  • In-licensing and/or R&D collaborations
  • Licensing our platform technologies
  • Development and commercial partnerships with other leading biopharma companies in order to maximize the global potential of our pipeline
  • Preclinical Research Collaborations to provide access to our therapeutic candidates, animal models, cell lines and other technologies
  • Investigator Initiated Studies to support external investigators interested in studying Regeneron products and drug candidates

OUR STRATEGY

We follow the science, rather than limiting our innovations to any one therapeutic area.

We are open to opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we are interested in partnering on:

  • Technologies to enable the discovery of next-generation, antibody-based therapeutics
  • Novel biomarkers and/or next-generation diagnostics to enable selection of optimal patient population and earlier detection of safety/efficacy signals
  • Drug delivery or formulation technologies that can improve the efficacy/safety/compliance profile of our therapeutic antibodies
  • Studying the potential of combinations involving molecules in Regeneron’s pipeline with other innovative clinical-stage therapeutic candidates
  • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery/validation and antibody discovery

SOME OF OUR CURRENT COLLABORATORS INCLUDE: